{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T07:01:50Z","timestamp":1791874910992,"version":"4.3.4"},"reference-count":120,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T00:00:00Z","timestamp":1571961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2019.02538","type":"journal-article","created":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T00:33:58Z","timestamp":1571963638000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":658,"title":["Pharmacological Inhibitors of the NLRP3 Inflammasome"],"prefix":"10.3389","volume":"10","author":[{"given":"Ayesha","family":"Zahid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bofeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud John Kombe","family":"Kombe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tengchuan","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhui","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,10,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1038\/nature08900","article-title":"Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity","volume":"464","author":"Neill","year":"2010","journal-title":"Nature"},{"key":"B2","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s00281-015-0503-7","article-title":"Role of innate immune system in systemic sclerosis","volume":"37","author":"Fullard","year":"2015","journal-title":"Semin Immunopathol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/S1097-2765(02)00599-3","article-title":"The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-\u03b2","volume":"10","author":"Martinon","year":"2002","journal-title":"Mol Cell."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e1813","DOI":"10.1038\/cddis.2015.186","article-title":"Single-cell imaging of inflammatory caspase dimerization reveals differential recruitment to inflammasomes","volume":"6","author":"Sanders","year":"2015","journal-title":"Cell Death Dis"},{"key":"B5","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.cell.2010.01.040","article-title":"The inflammasomes","volume":"140","author":"Schroder","year":"2010","journal-title":"Cell."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1002\/glia.22499","article-title":"Human astrocytes express a novel NLRP2 inflammasome","volume":"61","author":"Minkiewicz","year":"2013","journal-title":"Glia"},{"key":"B7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/imm.12081","article-title":"The role of interferon-\u03b2 in the treatment of multiple sclerosis and experimental autoimmune encephalomyelitis\u2013in the perspective of inflammasomes","volume":"139","author":"Inoue","year":"2013","journal-title":"Immunology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"7360","DOI":"10.1038\/ncomms8360","article-title":"Bruton's tyrosine kinase is essential for NLRP3 inflammasome activation and contributes to ischaemic brain injury","volume":"6","author":"Ito","year":"2015","journal-title":"Nat Commun"},{"key":"B9","doi-asserted-by":"publisher","first-page":"859145","DOI":"10.1155\/2013\/859145","article-title":"Nlrp3 inflammasome and MS\/EAE","volume":"2013","author":"Inoue","year":"2013","journal-title":"Autoimmune Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"333","DOI":"10.3389\/fimmu.2013.00333","article-title":"Functions of NOD-like receptors in human diseases","volume":"4","author":"Zhong","year":"2013","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/ni.1636","article-title":"The NALP3 inflammasome is involved in the innate immune response to amyloid-\u03b2","volume":"9","author":"Halle","year":"2008","journal-title":"Nat Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"8041","DOI":"10.1073\/pnas.0611496104","article-title":"Cryopyrin\/NALP3 binds ATP\/dATP, is an ATPase, and requires ATP binding to mediate inflammatory signaling","volume":"104","author":"Duncan","year":"2007","journal-title":"Proc Natl Acad Sci USA."},{"key":"B13","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41586-019-1295-z","article-title":"Structural mechanism for NEK7-licensed activation of NLRP3 inflammasome","volume":"570","author":"Sharif","year":"2019","journal-title":"Nature"},{"key":"B14","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/ni.2231","article-title":"Sensing and reacting to microbes through the inflammasomes","volume":"13","author":"Franchi","year":"2012","journal-title":"Nat Immunol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/nm.2717","article-title":"NLRP3 has a protective role in age-related macular degeneration through the induction of IL-18 by drusen components","volume":"18","author":"Doyle","year":"2012","journal-title":"Nat Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nature04516","article-title":"Gout-associated uric acid crystals activate the NALP3 inflammasome","volume":"440","author":"Martinon","year":"2006","journal-title":"Nature"},{"key":"B17","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/nature04515","article-title":"Cryopyrin activates the inflammasome in response to toxins and ATP","volume":"440","author":"Mariathasan","year":"2006","journal-title":"Nature."},{"key":"B18","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1038\/ni.1935","article-title":"Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1\u03b2 in type 2 diabetes","volume":"11","author":"Masters","year":"2010","journal-title":"Nat Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/cdd.2015.176","article-title":"Inflammasome-dependent IL-1\u03b2 release depends upon membrane permeabilisation","volume":"23","author":"Mart\u00edn-S\u00e1nchez","year":"2016","journal-title":"Cell Death Different"},{"key":"B20","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jmb.2017.11.013","article-title":"The NLRP3 inflammasome renders cell death pro-inflammatory","volume":"430","author":"Gaidt","year":"2018","journal-title":"J Mol Biol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/nrd.2018.97","article-title":"Targeting the NLRP3 inflammasome in inflammatory diseases","volume":"17","author":"Mangan","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"B22","doi-asserted-by":"publisher","first-page":"787","DOI":"10.4049\/jimmunol.0901363","article-title":"Cutting edge: NF-\u03baB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression","volume":"183","author":"Bauernfeind","year":"2009","journal-title":"J Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"4214","DOI":"10.4049\/jimmunol.1400582","article-title":"Cytosolic double-stranded RNA activates the NLRP3 inflammasome via MAVS-induced membrane permeabilization and K+ efflux","volume":"193","author":"Franchi","year":"2014","journal-title":"J Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"36617","DOI":"10.1074\/jbc.M112.407130","article-title":"Non-transcriptional priming and deubiquitination regulate NLRP3 inflammasome activation","volume":"287","author":"Juliana","year":"2012","journal-title":"J Biol Chem"},{"key":"B25","doi-asserted-by":"publisher","first-page":"3881","DOI":"10.4049\/jimmunol.1301974","article-title":"Inflammasome priming by LPS is dependent upon ERK signaling and proteasome function","volume":"192","author":"Ghonime","year":"2014","journal-title":"J Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.molcel.2012.11.009","article-title":"Deubiquitination of NLRP3 by BRCC3 critically regulates inflammasome activity","volume":"49","author":"Py","year":"2013","journal-title":"Mol Cell"},{"key":"B27","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12950-015-0086-z","article-title":"Increased expression of the NLRP3 inflammasome components in patients with Beh\u00e7et's disease","volume":"12","author":"Kim","year":"2015"},{"key":"B28","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2147\/JIR.S51250","article-title":"Targeting the NLRP3 inflammasome in chronic inflammatory diseases: current perspectives","volume":"8","author":"Ozaki","year":"2015","journal-title":"J Inflamm Res"},{"key":"B29","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/nyas.12458","article-title":"Mechanism of NLRP3 inflammasome activation","volume":"1319","author":"Sutterwala","year":"2014","journal-title":"Ann NY Acad Sci"},{"key":"B30","doi-asserted-by":"publisher","first-page":"5230","DOI":"10.4049\/jimmunol.1301490","article-title":"Mitochondrial reactive oxygen species induces NLRP3-dependent lysosomal damage and inflammasome activation","volume":"191","author":"Heid","year":"2013","journal-title":"J Immunol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.molmed.2014.11.008","article-title":"Mitochondria: diversity in the regulation of the NLRP3 inflammasome","volume":"21","author":"Gurung","year":"2015","journal-title":"Trends Mol Med"},{"key":"B32","doi-asserted-by":"crossref","first-page":"15195","DOI":"10.1016\/S0021-9258(17)36591-2","article-title":"Interleukin-1 beta maturation and release in response to ATP and nigericin. Evidence that potassium depletion mediated by these agents is a necessary and common feature of their activity","volume":"269","author":"Perregaux","year":"1994","journal-title":"J Biol Chem."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1038\/sj.cdd.4402195","article-title":"Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration","volume":"14","author":"P\u00e9trilli","year":"2007","journal-title":"Cell Death Different"},{"key":"B34","doi-asserted-by":"publisher","first-page":"32926","DOI":"10.1074\/jbc.M114.579961","article-title":"The lysosome rupture-activated TAK1-JNK pathway regulates NLRP3 inflammasome activation","volume":"289","author":"Okada","year":"2014","journal-title":"J Biol Chem"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1038\/nature08938","article-title":"NLRP3 inflamasomes are required for atherogenesis and activated by cholesterol crystals that form early in disease","volume":"464","author":"Duewell","year":"2010","journal-title":"Nature."},{"key":"B36","doi-asserted-by":"publisher","first-page":"194","DOI":"10.2337\/db12-0420","article-title":"Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes","volume":"62","author":"Lee","year":"2013","journal-title":"Diabetes"},{"key":"B37","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1097\/MCA.0000000000000255","article-title":"NLRP3 inflammasome in peripheral blood monocytes of acute coronary syndrome patients and its relationship with statins","volume":"26","author":"Altaf","year":"2015","journal-title":"Coron Artery Dis"},{"key":"B38","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1073\/pnas.1414536112","article-title":"Hematopoietic IKBKE limits the chronicity of inflammasome priming and metaflammation","volume":"112","author":"Patel","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.3892\/ijmm.2015.2129","article-title":"P2X7R is involved in the progression of atherosclerosis by promoting NLRP3 inflammasome activation","volume":"35","author":"Peng","year":"2015","journal-title":"Int J Mol Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1111\/cns.12349","article-title":"Activating cannabinoid receptor 2 alleviates pathogenesis of experimental autoimmune encephalomyelitis via activation of autophagy and inhibiting NLRP 3 inflammasome","volume":"20","author":"Shao","year":"2014","journal-title":"CNS Neurosci Ther"},{"key":"B41","doi-asserted-by":"publisher","first-page":"10480","DOI":"10.1073\/pnas.1201836109","article-title":"NLRP3 inflammasome induces chemotactic immune cell migration to the CNS in experimental autoimmune encephalomyelitis","volume":"109","author":"Inoue","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"B42","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1111\/imm.12442","article-title":"Effect of enterohaemorrhagic Escherichia coli O 157: H 7-specific enterohaemolysin on interleukin-1\u03b2 production differs between human and mouse macrophages due to the different sensitivity of NLRP 3 activation","volume":"145","author":"Cheng","year":"2015","journal-title":"Immunology"},{"key":"B43","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.intimp.2014.12.009","article-title":"Asiatic acid ameliorates dextran sulfate sodium-induced murine experimental colitis via suppressing mitochondria-mediated NLRP3 inflammasome activation","volume":"24","author":"Guo","year":"2015","journal-title":"Int Immunopharmacol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.bcp.2015.02.002","article-title":"Wogonoside protects against dextran sulfate sodium-induced experimental colitis in mice by inhibiting NF-\u03baB and NLRP3 inflammasome activation","volume":"94","author":"Sun","year":"2015","journal-title":"Biochem pharmacol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s13238-013-0001-4","article-title":"Inflammasomes in cancer: a double-edged sword","volume":"5","author":"Kolb","year":"2014","journal-title":"Protein Cell."},{"key":"B46","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1158\/2326-6066.CIR-16-0269","article-title":"Inflammasomes and cancer","volume":"5","author":"Karki","year":"","journal-title":"Cancer Immunol Res"},{"key":"B47","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1111\/j.1365-2249.2011.04535.x","article-title":"Immunology in clinic review series; focus on autoinflammatory diseases: role of inflammasomes in autoinflammatory syndromes","volume":"167","author":"Ozkurede","year":"2012","journal-title":"Clin Exp Immunol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1083\/jcb.200903124","article-title":"Glyburide inhibits the Cryopyrin\/Nalp3 inflammasome","volume":"187","author":"Lamkanfi","year":"2009","journal-title":"J Cell Biol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/nm.3804","article-title":"The ketone metabolite \u03b2-hydroxybutyrate blocks NLRP3 inflammasome\u2013mediated inflammatory disease","volume":"21","author":"Youm","year":"2015","journal-title":"Nat Med."},{"key":"B50","doi-asserted-by":"publisher","first-page":"e85765","DOI":"10.1371\/journal.pone.0085765","article-title":"Antimicrobial cathelicidin peptide LL-37 inhibits the LPS\/ATP-induced pyroptosis of macrophages by dual mechanism","volume":"9","author":"Hu","year":"2014","journal-title":"PLoS ONE."},{"key":"B51","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s00395-014-0415-z","article-title":"TXNIP mediates NLRP3 inflammasome activation in cardiac microvascular endothelial cells as a novel mechanism in myocardial ischemia\/reperfusion injury","volume":"109","author":"Liu","year":"2014","journal-title":"Basic Res Cardiol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1084\/jem.20171419","article-title":"Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders","volume":"214","author":"Jiang","year":"2017","journal-title":"J Exp Med"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1074\/jbc.M113.515080","article-title":"3, 4-methylenedioxy-\u03b2-nitrostyrene inhibits NLRP3 inflammasome activation by blocking assembly of the inflammasome","volume":"289","author":"He","year":"2014","journal-title":"J Biol Chem"},{"key":"B54","first-page":"187","article-title":"Identification and characterization of a novel class of interleukin-1 post-translational processing inhibitors","volume":"299","author":"Perregaux","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/FJC.0000000000000247","article-title":"Pharmacologic inhibition of the NLRP3 inflammasome preserves cardiac function after ischemic and non-ischemic injury in the mouse","volume":"66","author":"Marchetti","year":"2015","journal-title":"J Cardiovasc Pharmacol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1097\/FJC.0000000000000053","article-title":"A novel pharmacologic inhibitor of the NLRP3 inflammasome limits myocardial injury following ischemia-reperfusion in the mouse","volume":"63","author":"Marchetti","year":"2014","journal-title":"J Cardiovasc Pharmacol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s12974-019-1471-y","article-title":"A novel small molecular NLRP3 inflammasome inhibitor alleviates neuroinflammatory response following traumatic brain injury","volume":"16","author":"Kuwar","year":"2019","journal-title":"J Neuroinflamm."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1016\/j.bcp.2013.03.008","article-title":"A novel benzo[d]imidazole derivate prevents the development of dextran sulfate sodium-induced murine experimental colitis via inhibition of NLRP3 inflammasome","volume":"85","author":"Liu","year":"2013","journal-title":"Biochem Pharmacol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"9792","DOI":"10.1074\/jbc.M109.082305","article-title":"Anti-inflammatory compounds parthenolide and Bay 11\u20137082 are direct inhibitors of the inflammasome","volume":"285","author":"Juliana","year":"2010","journal-title":"J Biol Chem"},{"key":"B60","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1165\/rcmb.2006-0323OC","article-title":"Parthenolide inhibits I\u03baB Kinase, NF-\u03baB activation, and inflammatory response in cystic fibrosis cells and mice","volume":"36","author":"Saadane","year":"2007","journal-title":"Am J Respir Cell Mol Biol"},{"key":"B61","article-title":"A Small Molecule Inhibitor of Caspase 1","volume-title":"Probe Reports from the NIH Molecular Libraries Program [Internet]","author":"Boxer","year":"2010"},{"key":"B62","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/S1063-4584(03)00153-5","article-title":"Pralnacasan, an inhibitor of interleukin-1\u03b2 converting enzyme, reduces joint damage in two murine models of osteoarthritis","volume":"11","author":"Rudolphi","year":"2003","journal-title":"Osteoarthritis Cartilage"},{"key":"B63","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1124\/jpet.106.111344","article-title":"(S)-1-((S)-2-{[1-(4-Amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an Orally Available Selective Interleukin (IL)-Converting Enzyme\/Caspase-1 Inhi","volume":"321","author":"Wannamaker","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"B64","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1042\/BJ20121651","article-title":"The anti-inflammatory drug BAY 11\u20137082 suppresses the MyD88-dependent signalling network by targeting the ubiquitin system","volume":"451","author":"Strickson","year":"2013","journal-title":"Biochem J"},{"key":"B65","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/j.1365-2141.2009.07988.x","article-title":"IKK inhibitor bay 11-7082 induces necroptotic cell death in precursor-B acute lymphoblastic leukaemic blasts","volume":"148","author":"Meng","year":"2010","journal-title":"Br J Haematol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1111\/febs.12283","article-title":"The anti-inflammatory compound BAY 11\u20137082 is a potent inhibitor of Protein Tyrosine Phosphatases","volume":"280","author":"Krishnan","year":"2013","journal-title":"FEBS J"},{"key":"B67","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nm.3806","article-title":"A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases","volume":"21","author":"Coll","year":"2015","journal-title":"Nat Med."},{"key":"B68","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41589-019-0277-7","article-title":"MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition","volume":"15","author":"Coll","year":"2019","journal-title":"Nat Chem Biol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"e8689","DOI":"10.15252\/emmm.201708689","article-title":"Tranilast directly targets NLRP3 to treat inflammasome-driven diseases","volume":"10","author":"Huang","year":"2018","journal-title":"EMBO Mol Med"},{"key":"B70","doi-asserted-by":"publisher","first-page":"E1530","DOI":"10.1073\/pnas.1716095115","article-title":"OLT1177, a \u03b2-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation","volume":"115","author":"Marchetti","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"B71","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1038\/s41467-018-04947-6","article-title":"Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity","volume":"9","author":"He","year":"2018","journal-title":"Nat Commun"},{"key":"B72","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1210\/jc.2002-021971","article-title":"Editorial: sulfonylureas differ in effects on ischemic preconditioning\u2013is it time to retire glyburide?","volume":"88","author":"Riddle","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"B73","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1172\/JCI25495","article-title":"ATP-sensitive potassium channelopathies: focus on insulin secretion","volume":"115","author":"Ashcroft","year":"2005","journal-title":"J Clin Invest"},{"key":"B74","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nature02664","article-title":"Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf","volume":"430","author":"Mariathasan","year":"2004","journal-title":"Nature."},{"key":"B75","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1182\/blood.V90.8.2911","article-title":"Interleukin-1beta secretion is impaired by inhibitors of the Atp binding cassette transporter, ABC1","volume":"90","author":"Hamon","year":"1997","journal-title":"Blood"},{"key":"B76","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1046\/j.0022-202x.2001.01451.x","article-title":"Inhibition of ATP-binding cassette transporter downregulates interleukin-1beta-mediated autocrine activation of human dermal fibroblasts","volume":"117","author":"Lottaz","year":"2001","journal-title":"J Invest Dermatol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"5412","DOI":"10.1021\/acs.jmedchem.8b00733","article-title":"Structural insights of benzenesulfonamide analogues as NLRP3 inflammasome inhibitors: design, synthesis, and biological characterization","volume":"61","author":"Fulp","year":"2018","journal-title":"J Med Chem."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1007\/s12035-017-0467-9","article-title":"NLRP3 inflammasome inhibitor ameliorates amyloid pathology in a mouse model of Alzheimer's disease","volume":"55","author":"Yin","year":"2018","journal-title":"Mol Neurobiol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1146\/annurev.pharmtox.38.1.539","article-title":"Ethnopharmacology of Mexican asteraceae (compositae)","volume":"38","author":"Heinrich","year":"1998","journal-title":"Ann Rev Pharmacol Toxicol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"4427","DOI":"10.1182\/blood-2007-05-090621","article-title":"An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells","volume":"110","author":"Guzman","year":"2007","journal-title":"Blood."},{"key":"B81","doi-asserted-by":"publisher","first-page":"e891","DOI":"10.1038\/cddis.2013.415","article-title":"Parthenolide generates reactive oxygen species and autophagy in MDA-MB231 cells. A soluble parthenolide analogue inhibits tumour growth and metastasis in a xenograft model of breast cancer","volume":"4","author":"D'anneo","year":"2013","journal-title":"Cell Death Dis."},{"key":"B82","doi-asserted-by":"publisher","first-page":"568","DOI":"10.4049\/jimmunol.168.6.3024","article-title":"The potential for caspases in drug discovery","volume":"13","author":"Mackenzie","year":"2010","journal-title":"Curr Opin Drug Discov Devel"},{"key":"B83","first-page":"154","article-title":"Pralnacasan (vertex pharmaceuticals)","volume":"6","author":"Siegmund","year":"2003","journal-title":"IDrugs"},{"key":"B84","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/ar2555","article-title":"Randomized controlled trial design in rheumatoid arthritis: the past decade","volume":"11","author":"Strand","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"B85","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/sj.cdd.4401556","article-title":"Apoptosis-based therapies and drug targets","volume":"12","author":"Fischer","year":"2005","journal-title":"Cell Death Different"},{"key":"B86","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1111\/j.1365-2796.2011.02431.x","article-title":"Interleukin-1 type 1 receptor\/Toll-like receptor signalling in epilepsy: the importance of IL-1beta and high-mobility group box 1","volume":"270","author":"Maroso","year":"2011","journal-title":"J Int Med"},{"key":"B87","doi-asserted-by":"publisher","first-page":"3916","DOI":"10.1038\/s41467-018-06449-x","article-title":"Caspase-1 inhibition alleviates cognitive impairment and neuropathology in an Alzheimer's disease mouse model","volume":"9","author":"Flores","year":"2018","journal-title":"Nat Commun"},{"key":"B88","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s00395-018-0692-z","article-title":"Caspase-1 inhibition by VX-765 administered at reperfusion in P2Y12 receptor antagonist-treated rats provides long-term reduction in myocardial infarct size and preservation of ventricular function","volume":"113","author":"Audia","year":"2018","journal-title":"Basic Res Cardiol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"25697","DOI":"10.1074\/jbc.M109.014340","article-title":"Vinyl sulfones as antiparasitic agents and a structural basis for drug design","volume":"284","author":"Kerr","year":"2009","journal-title":"J Biol Chem"},{"key":"B90","doi-asserted-by":"publisher","first-page":"12504","DOI":"10.1038\/ncomms12504","article-title":"Fenamate NSAIDs inhibit the NLRP3 inflammasome and protect against Alzheimer's disease in rodent models","volume":"7","author":"Daniels","year":"2016","journal-title":"Nat Commun"},{"key":"B91","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.bbi.2016.12.014","article-title":"Inhibiting the NLRP3 inflammasome with MCC950 promotes non-phlogistic clearance of amyloid-\u03b2 and cognitive function in APP\/PS1 mice","volume":"61","author":"Dempsey","year":"2017","journal-title":"Brain Behav Immun"},{"key":"B92","doi-asserted-by":"publisher","first-page":"634493","DOI":"10.1101\/634493","article-title":"MCC950\/CRID3 potently targets the NACHT domain of wildtype NLRP3 but not disease-associated mutants for inflammasome inhibition","author":"Vande Walle","year":"2019","journal-title":"bioRxiv"},{"key":"B93","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.4049\/jimmunol.1600035","article-title":"Efficacy and pharmacology of the NLRP3 inflammasome inhibitor CP-456,773 (CRID3) in murine models of dermal and pulmonary inflammation","volume":"197","author":"Primiano","year":"2016","journal-title":"J Immunol"},{"key":"B94","doi-asserted-by":"publisher","first-page":"eaah4066","DOI":"10.1126\/scitranslmed.aah4066","article-title":"Inflammasome inhibition prevents \u03b1-synuclein pathology and dopaminergic neurodegeneration in mice","volume":"10","author":"Gordon","year":"2018","journal-title":"Sci Trans Med."},{"key":"B95","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1172\/JCI16112","article-title":"Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxin\u2013induced intestinal fluid secretion","volume":"110","author":"Ma","year":"2002","journal-title":"J Clin Invest"},{"key":"B96","doi-asserted-by":"publisher","first-page":"8187","DOI":"10.1016\/j.bmc.2008.07.044","article-title":"Thiazolidinone CFTR inhibitors with improved water solubility identified by structure\u2013activity analysis","volume":"16","author":"Sonawane","year":"2008","journal-title":"Bioorgan Med Chem"},{"key":"B97","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.phrs.2014.10.009","article-title":"Tranilast: a review of its therapeutic applications","volume":"91","author":"Darakhshan","year":"2015","journal-title":"Pharmacol Res"},{"key":"B98","first-page":"141","article-title":"Tranilast Kissei pharmaceutical","volume":"1","author":"Konneh","year":"1998","journal-title":"IDrugs"},{"key":"B99","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1126\/science.1117634","article-title":"Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite","volume":"310","author":"Platten","year":"2005","journal-title":"Science"},{"key":"B100","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nrcardio.2017.161","article-title":"The NLRP3 inflammasome in acute myocardial infarction","volume":"15","author":"Toldo","year":"2018","journal-title":"Nat Rev Cardiol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S0934-8840(97)80076-X","article-title":"Antibacterial activity of trichorabdal A from Rabdosia trichocarpa against Helicobacter pylori","volume":"286","author":"Kadota","year":"1997","journal-title":"Zentralblatt Bakteriol"},{"key":"B102","doi-asserted-by":"publisher","first-page":"3327","DOI":"10.3390\/molecules19033327","article-title":"Intracellular glutathione depletion by oridonin leads to apoptosis in hepatic stellate cells","volume":"19","author":"Kuo","year":"2014","journal-title":"Molecules"},{"key":"B103","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.ejmech.2016.06.015","article-title":"Discovery and development of natural product oridonin-inspired anticancer agents","volume":"122","author":"Ding","year":"2016","journal-title":"Eur J Med Chem"},{"key":"B104","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1248\/cpb.24.2118","article-title":"The antitumor and antibacterial activity of the Isodon diterpenoids","volume":"24","author":"Fujita","year":"1976","journal-title":"Chem Pharm Bull"},{"key":"B105","doi-asserted-by":"publisher","first-page":"261","DOI":"10.18926\/AMO\/31960","article-title":"A comparison of the signal pathways between the TNF\u03b1-and oridonin-induced Murine L929 fibrosarcoma cell death","volume":"59","author":"Huang","year":"2005","journal-title":"Acta Med Okayama"},{"key":"B106","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.intimp.2009.01.002","article-title":"Multiple-modulation effects of Oridonin on the production of proinflammatory cytokines and neurotrophic factors in LPS-activated microglia","volume":"9","author":"Xu","year":"2009","journal-title":"Int Immunopharmacol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"68153","DOI":"10.18632\/oncotarget.19249","article-title":"Oridonin attenuates the release of pro-inflammatory cytokines in lipopolysaccharide-induced RAW264. 7 cells and acute lung injury","volume":"8","author":"Zhao","year":"2017","journal-title":"Oncotarget"},{"key":"B108","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1111\/jgh.12710","article-title":"Oridonin's therapeutic effect: Suppressing T h1\/T h17 simultaneously in a mouse model of C rohn's disease","volume":"30","author":"Wang","year":"2015","journal-title":"J Gastroenterol Hepatol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"e104745","DOI":"10.1371\/journal.pone.0104745","article-title":"Oridonin attenuates A\u03b21\u201342-induced neuroinflammation and inhibits NF-\u03baB pathway","volume":"9","author":"Wang","year":"2014","journal-title":"PLoS ONE"},{"key":"B110","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1111\/jcmm.12124","article-title":"Oridonin ameliorates neuropathological changes and behavioural deficits in a mouse model of cerebral amyloidosis","volume":"17","author":"Zhang","year":"2013","journal-title":"J Cell Mol Med"},{"key":"B111","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.canlet.2018.01.034","article-title":"The NLRP3 inflammasome: role in metabolic disorders and regulation by metabolic pathways","volume":"419","author":"Jiang","year":"2018","journal-title":"Cancer Lett"},{"key":"B112","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.smim.2013.10.008","article-title":"Treating inflammation by blocking interleukin-1 in humans","volume":"25","author":"Dinarello","year":"2013","journal-title":"Semin Immunol."},{"key":"B113","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/j.cell.2015.10.072","article-title":"Epithelial IL-18 equilibrium controls barrier function in colitis","volume":"163","author":"Nowarski","year":"2015","journal-title":"Cell"},{"key":"B114","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1038\/nature11290","article-title":"Novel role of PKR in inflammasome activation and HMGB1 release","volume":"488","author":"Lu","year":"2012","journal-title":"Nature"},{"key":"B115","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1084\/jem.20172060","article-title":"GSDMD is critical for autoinflammatory pathology in a mouse model of Familial Mediterranean Fever","volume":"215","author":"Kanneganti","year":"2018"},{"key":"B116","doi-asserted-by":"publisher","first-page":"e3000047","DOI":"10.1371\/journal.pbio.3000047","article-title":"Gasdermin D mediates the pathogenesis of neonatal-onset multisystem inflammatory disease in mice","volume":"16","author":"Xiao","year":"2018","journal-title":"PLoS Biol"},{"key":"B117","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.15252\/embj.201695415","article-title":"Pore formation by GSDMD is the effector mechanism of pyroptosis","volume":"35","author":"Gaidt","year":"2016","journal-title":"EMBO J"},{"key":"B118","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nature18629","article-title":"Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores","volume":"535","author":"Liu","year":"2016","journal-title":"Nature"},{"key":"B119","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1007\/s00216-019-01633-4","article-title":"Nanobody: outstanding features for diagnostic and therapeutic applications","volume":"411","author":"Salvador","year":"2019","journal-title":"Anal Bioanal Chem"},{"key":"B120","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.sbi.2016.10.019","article-title":"Camelid and shark single domain antibodies: structural features and therapeutic potential","volume":"45","author":"Konning","year":"2017","journal-title":"Curr Opin Struct Biol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.02538\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,25]],"date-time":"2021-01-25T20:52:55Z","timestamp":1611607975000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.02538\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,25]]},"references-count":120,"alternative-id":["10.3389\/fimmu.2019.02538"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2019.02538","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,25]]},"article-number":"2538"}}